These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10660343)

  • 1. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online.
    Walker AH; Jaffe JM; Gunasegaram S; Cummings SA; Huang CS; Chern HD; Olopade OI; Weber BL; Rebbeck TR
    Hum Mutat; 1998; 12(4):289. PubMed ID: 10660343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.
    Paris PL; Kupelian PA; Hall JM; Williams TL; Levin H; Klein EA; Casey G; Witte JS
    Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):901-5. PubMed ID: 10548319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?
    Kittles RA; Chen W; Panguluri RK; Ahaghotu C; Jackson A; Adebamowo CA; Griffin R; Williams T; Ukoli F; Adams-Campbell L; Kwagyan J; Isaacs W; Freeman V; Dunston GM
    Hum Genet; 2002 Jun; 110(6):553-60. PubMed ID: 12107441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
    Zeigler-Johnson CM; Walker AH; Mancke B; Spangler E; Jalloh M; McBride S; Deitz A; Malkowicz SB; Ofori-Adjei D; Gueye SM; Rebbeck TR
    Hum Hered; 2002; 54(1):13-21. PubMed ID: 12446983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
    Rebbeck TR
    J Natl Cancer Inst; 2000 Jan; 92(1):76. PubMed ID: 10620637
    [No Abstract]   [Full Text] [Related]  

  • 6. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4.
    Ball SE; Scatina J; Kao J; Ferron GM; Fruncillo R; Mayer P; Weinryb I; Guida M; Hopkins PJ; Warner N; Hall J
    Clin Pharmacol Ther; 1999 Sep; 66(3):288-94. PubMed ID: 10511065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity.
    Sata F; Sapone A; Elizondo G; Stocker P; Miller VP; Zheng W; Raunio H; Crespi CL; Gonzalez FJ
    Clin Pharmacol Ther; 2000 Jan; 67(1):48-56. PubMed ID: 10668853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
    Ando Y; Tateishi T; Sekido Y; Yamamoto T; Satoh T; Hasegawa Y; Kobayashi S; Katsumata Y; Shimokata K; Saito H
    J Natl Cancer Inst; 1999 Sep; 91(18):1587-90. PubMed ID: 10491442
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.
    Schirmer M; Toliat MR; Haberl M; Suk A; Kamdem LK; Klein K; Brockmöller J; Nürnberg P; Zanger UM; Wojnowski L
    Pharmacogenet Genomics; 2006 Jan; 16(1):59-71. PubMed ID: 16344723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
    Bangsi D; Zhou J; Sun Y; Patel NP; Darga LL; Heilbrun LK; Powell IJ; Severson RK; Everson RB
    Urol Oncol; 2006; 24(1):21-7. PubMed ID: 16414488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
    Rebbeck TR; Jaffe JM; Walker AH; Wein AJ; Malkowicz SB
    J Natl Cancer Inst; 1998 Aug; 90(16):1225-9. PubMed ID: 9719084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic contribution to variable human CYP3A-mediated metabolism.
    Lamba JK; Lin YS; Schuetz EG; Thummel KE
    Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls.
    Tang YM; Green BL; Chen GF; Thompson PA; Lang NP; Shinde A; Lin DX; Tan W; Lyn-Cook BD; Hammons GJ; Kadlubar FF
    Pharmacogenetics; 2000 Dec; 10(9):761-6. PubMed ID: 11221602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
    Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.
    Lamba JK; Lin YS; Thummel K; Daly A; Watkins PB; Strom S; Zhang J; Schuetz EG
    Pharmacogenetics; 2002 Mar; 12(2):121-32. PubMed ID: 11875366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.
    Westlind A; Löfberg L; Tindberg N; Andersson TB; Ingelman-Sundberg M
    Biochem Biophys Res Commun; 1999 May; 259(1):201-5. PubMed ID: 10334940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.
    Plummer SJ; Conti DV; Paris PL; Curran AP; Casey G; Witte JS
    Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):928-32. PubMed ID: 14504207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP3A4: a potential prostate cancer risk factor for high-risk groups.
    Zeigler-Johnson C
    Clin J Oncol Nurs; 2001; 5(4):153-4. PubMed ID: 12690615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations.
    Tayeb MT; Clark C; Ameyaw MM; Haites NE; Evans DA; Tariq M; Mobarek A; Ofori-Adjei D; McLeod HL
    Pharmacogenetics; 2000 Nov; 10(8):753-6. PubMed ID: 11186137
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk.
    Jernström H; Chu W; Vesprini D; Tao Y; Majeed N; Deal C; Pollak M; Narod SA
    Mol Genet Metab; 2001 Feb; 72(2):144-54. PubMed ID: 11161840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.